李桂兰.基础胰岛素联合DPP-4抑制剂对2型糖尿病患者的临床研究[J].内科急危重症杂志,2015,21(4):
扫码阅读全文
|
| DOI： |
| 中文关键词: 2型糖尿病 DPP-4抑制剂 胰岛素 |
| 英文关键词:Type 2 diabetes DPP- 4 inhibitors Insulin |
| 基金项目: |
|
| 摘要点击次数: 4364 |
| 全文下载次数: 5471 |
| 中文摘要: |
| 摘要:目的：探讨基础胰岛素联合二肽基肽酶Ⅳ (DPP-4)抑制剂在治疗2型糖尿病方面的临床疗效。方法：选择我院2012年7月至2014年7月收治的80例2型糖尿病（FBS＞11.1mmol/L）患者，随机进行分组，治疗组与对照组，各40例，全部患者均给予生活方式干预，治疗组给予地特胰岛素联合西格列汀100mg，每日服用一次，餐前口服；对照组给予地特胰岛素联合瑞格那奈1mg，每日服用三次，三餐前口服治疗。结果：经治疗16周后，治疗组患者在空腹及餐后两小时血糖（PBG、2hPBG），HBA1C，血脂谱，体重指数（BMI）较前明显下降，具有统计学意义（P＜0.05）；与对照组比较，结果具有显著性差异（P＜0.05）；两组患者比较，胰岛β功能均较治疗前明显下降，但治疗组改善情况更为明显（P＜0.05）；治疗期间，两组患者均未出现低血糖反应，未见其它临床不良反应，两组比较，无显著性差异（P>0.05）。治疗组患者血糖达标率显著高于对照组，血糖达标中位时间显著短于对照组，两组数据具有显著性差异（P<0.05）。结论：基础胰岛素联合DPP-4抑制剂在治疗2型糖尿病方面具有较好的临床疗效，且治疗安全性高。
关键词:2型糖尿病；DPP-4抑制剂；胰岛素 |
| 英文摘要: |
| Abstract: Objective: To study the basic insulin joint DPP 4 inhibitors in the treatment of type 2 diabetes mellitus in the cl[作者简介：张云林，男，（1977-），硕士学历，副主任医师，从事内分泌专业工作，邮箱：zhangyunlinxx@163.com，通讯作者：李桂兰，女，（1980-），大学本科，主管护师，邮箱：liguilan1980@163.com
]inical curative effect.Methods: Our hospital from July 2012 to July 2014 were treated 80 cases of type 2 diabetes (FBS tendency > 11.1 L) patients, based on the principle of random, divided the patients into the treatment group 40 cases and control group 40 cases, all patients were given lifestyle intervention, treatment group was given to insulin joint west Glenn dean 100 mg, 1 day/time, pre-dinner oral;The control group given to Craig that nai insulin joint treatment.Results: After treatment, the treatment group patients in the two hours fasting and postprandial blood glucose (PBG, 2 HPBG), HBA1C, blood lipid, body mass index (BMI) significantly lower earlier, with statistical significance (P < 0.05), and compared with control group, the results have significant difference (P＜ 0.05);Two groups of patients were compared, islet beta function was significantly decreased, the but the treatment group improved more significantly (P < 0.05), treatment group patients did not appear hypoglycemia, did not see other clinical adverse reactions, comparing the two groups, there was no significant difference (P > 0.05). Two groups of patients with blood sugar success rate and blood glucose control is at the median time to compare the results with significant difference (P < 0.05).Conclusion: Basic insulin joint DPP 4 inhibitors in the treatment of type 2 diabetes has better clinical curative effect, and treatment of high safety, clinical application and dissemination.
Key words:Type 2 diabetes；DPP- 4 inhibitors； Insulin |
|
|
|
|
